Home › Drug Product Listings

Drug Product Listings

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database
A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)
Generic Name Common Trade Name(s) Classification Date Marketed in Canada (yyyy/mm/dd)sort icon
Alpelisib Piqray Antineoplastic agent 2020/03/11
Patiromer Veltassa Potassium binder 2020/03/09
Baloxavir marboxil Xofluza Antiviral agent 2020/02/19
Gilteritinib Xospata Antineoplastic agent 2020/02/03
Prasugrel Effient Antiplatelet agent 2020/01/31
Upadacitinib Rinvoq Disease-modifying antirheumatic agent 2020/01/16
Niraparib Zejula Antineoplastic agent 2020/01/09
Erdafitinib Balversa Protein kinase inhibitor 2019/12/09
Axicabtagene ciloleucel Yescarta Antineoplastic agent 2019/11/27
Glucagon Baqsimi Hyperglycemic agent 2019/11/20
Edaravone Radicava Treatment for amyotrophic lateral sclerosis 2019/10/29
Sodium zirconium cyclosilicate Lokelma Potassium binder 2019/10/17
Galcanezumab Emgality CGRP binding antibody 2019/10/02
Romosozumab Evenity Bone formation agent 2019/08/12
Safinamide Onstryv Monoamine oxidase B inhibitor 2019/07/10
Larotrectinib Vitrakvi Antineoplastic agent 2019/07/10
Abemaciclib Verzenio Protein kinase inhibitor 2019/07/03
Cemiplimab Libtayo Antineoplastic agent 2019/05/24
Risankizumab Skyrizi Interleukin-23 inihbitor 2019/05/13
Lorlatinib Lorbrena Tyrosine kinase inhibitor 2019/04/22
Dacomitinib Vizimpro Tyrosine kinase inhibitor 2019/04/22
Suvorexant Belsomra Hypnotic 2019/04/16
Enasidenib IDHIFA Antineoplastic agent / IDH2 Inhibitor 2019/02/27
Buprenorphine Sublocade Partial opioid agonist 2019
Doravirine + Lamivudine + Tenofovir Delstrigo Antiviral agent 2018/12/15
Burosumab Crysvita Fibroblast growth factor 23 (FGF23) Inhibitor 2018/12/05
Ribociclib Kisqali Antineoplastic agent 2018/11/26
Doravirine Pifeltro NNRTI 2018/11/15
Ivermectin Stromectol Anthelmintic 2018/11/07
Elagolix Orilissa Gonadotropin releasing hormone receptor antagonist 2018/10/31
Telotristat ethyl Xermelo Tryptophan hydroxylase inhibitor 2018/10/12
Cabozantinib Cabometyx Antineoplastic agent 2018/09/14
Crisaborole Eucrisa PDE-4 inhibitor 2018/08/29
Baricitinib Olumiant Immunosuppressant 2018/08/17
Erenumab Aimovig Anti-calcitonin gene-related peptide receptor 2018/08/01
Apalutamide Erleada Anti-androgen 2018/07/27
Syndicate content